(Q37938694)

25 August 2017

1 reference

title

How can we improve clinical trials in amyotrophic lateral sclerosis? (English)

1 reference

amyotrophic lateral sclerosis

25 August 2017

main subject

0 references

author

Paul H. Gordon

series ordinal

1

1 reference

25 August 2017

2

Vincent Meininger

1 reference

25 August 2017

language of work or name

English

0 references

publication date

27 September 2011

1 reference

25 August 2017

published in

Nature Reviews Neurology

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

650-654

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.147

25 August 2017

exact match

0 references

cites work

Lithium time-to-event trial in amyotrophic lateral sclerosis stops early for futility

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

ALS drug development: reflections from the past and a way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Guidelines for preclinical animal research in ALS/MND: A consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Randomized control trials in ALS: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Current hypotheses for the underlying biology of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

ALS: a disease of motor neurons and their nonneuronal neighbors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Focality of upper and lower motor neuron degeneration at the clinical onset of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Drug development for cancer chemoprevention: focus on molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Strategies for targeting tumors and tumor vasculature for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Mechanisms underlying inflammation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Systemic inflammatory cells fight off neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Gene-environment interactions: key to unraveling the mystery of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Predicting Parkinson's disease - why, when, and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Biomarkers for the early detection of Parkinson's and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Preclinical and subclinical events in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Programmed cell death in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Design, power, and interpretation of studies in the standard murine model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Minocycline for patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Design of phase II ALS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A score test for association of a longitudinal marker and an event with missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Amyotrophic lateral sclerosis-Evolutionary and other perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Recent advances in the genetics of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Biomarkers in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

The application of biomarkers in clinical trials for motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

The use of statistical MUNE in a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Diffusion tensor MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Brain perfusion imaging in amyotrophic lateral sclerosis: extent of cortical changes according to the severity and topography of motor impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

We have a problem: why have ALS trials been negative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

ALS pathogenesis: recent insights from genetics and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Statistical motor unit number estimation and ALS trials: the effect of motor unit instability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Trial of celecoxib in amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.147

Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: A six-month longitudinal study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21947135

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Brain and plasma riluzole pharmacokinetics: effect of minocycline combination

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21947135

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2011.147

1 reference

25 August 2017

1 reference